These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33665728)

  • 21. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
    Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
    Mohamed MF; Trueman S; Othman AA; Han JH; Ju TR; Marroum P
    AAPS J; 2019 Oct; 21(6):108. PubMed ID: 31654328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro release and bioaccessibility of oral solid preparations in a dynamic gastrointestinal system simulating fasted and fed states: A case study of metformin hydrochloride tablets.
    Yang S; Hu Z; Wu P; Kirk T; Chen XD
    Int J Pharm; 2024 Mar; 652():123869. PubMed ID: 38296171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
    Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
    Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.
    González-García I; García-Arieta A; Merino-Sanjuan M; Mangas-Sanjuan V; Bermejo M
    Eur J Pharm Sci; 2018 Jul; 119():200-207. PubMed ID: 29680456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study.
    Shin S; Kim TH; Lee DY; Chung SE; Lee JB; Kim DH; Shin BS
    AAPS J; 2020 Jan; 22(2):27. PubMed ID: 31938935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time Scaling for In Vitro-In Vivo Correlation: the Inverse Release Function (IRF) Approach.
    Cardot JM; Lukas JC; Muniz P
    AAPS J; 2018 Aug; 20(6):95. PubMed ID: 30159772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologically Based Dissolution Testing in a Drug Development Process-a Case Study of a Successful Application in a Bioequivalence Study of Trazodone ER Formulations Under Fed Conditions.
    Danielak D; Milanowski B; Wentowski K; Nogowska M; Kątny M; Rogowski P; Konwicki Ł; Puk E; Pieczuro J; Bawiec M; Garbacz G; Lulek J
    AAPS PharmSciTech; 2020 Jun; 21(5):161. PubMed ID: 32488427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
    Tang W; Engman H; Zhu Y; Dayton B; Boulton DW
    Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
    Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
    AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioequivalence of Dapagliflozin/Metformin Extended-release Fixed-combination Drug Product and Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Russian Subjects.
    Khomitskaya Y; Tikhonova N; Gudkov K; Erofeeva S; Holmes V; Dayton B; Davies N; Boulton DW; Tang W
    Clin Ther; 2018 Apr; 40(4):550-561.e3. PubMed ID: 29548719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet.
    Cheng CL; Yu LX; Lee HL; Yang CY; Lue CS; Chou CH
    Eur J Pharm Sci; 2004 Jul; 22(4):297-304. PubMed ID: 15196586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(3-4):167-84. PubMed ID: 23457958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult Chinese subjects.
    Gummesson A; Li H; Gillen M; Xu J; Niazi M; Hirshberg B
    Clin Drug Investig; 2014 Nov; 34(11):763-72. PubMed ID: 25269885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.
    Mittapalli RK; Nuthalapati S; Delke DeBord AE; Xiong H
    Pharm Res; 2017 Jun; 34(6):1187-1192. PubMed ID: 28243955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics.
    Kim TH; Bulitta JB; Kim DH; Shin S; Shin BS
    Int J Pharm; 2019 Feb; 556():276-286. PubMed ID: 30543888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester.
    Taha NF; Emara LH
    AAPS PharmSciTech; 2022 Jul; 23(6):202. PubMed ID: 35882726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of in vitro-in vivo correlation to predict the pharmacokinetics of several products containing a BCS class 1 drug in extended release matrices.
    Mirza T; Bykadi SA; Ellison CD; Yang Y; Davit BM; Khan MA
    Pharm Res; 2013 Jan; 30(1):179-90. PubMed ID: 22910891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability.
    Kakhi M; Marroum P; Chittenden J
    Biopharm Drug Dispos; 2013 Jul; 34(5):262-77. PubMed ID: 23097186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.